公开(公告)号：EP3009518A4

公开(公告)日：2017-01-04

申请号：EP14811138

申请日：2014-06-11

申请人： NAT CENTER OF NEUROLOGY AND PSYCHIATRY ,  CHUGAI PHARMACEUTICAL CO LTD

发明人： YAMAMURA TAKASHI ,  NAKAMURA MASAKAZU

IPC分类号： C12Q1/06 ,  A61K39/395 ,  A61K45/00 ,  A61P25/00 ,  C07K16/28 ,  G01N33/50 ,  G01N33/564

CPC分类号： G01N33/564 ,  A61K45/00 ,  C07K16/2866 ,  C07K2317/76 ,  G01N33/5052 ,  G01N2333/5412 ,  G01N2333/565 ,  G01N2333/70596 ,  G01N2800/285 ,  G01N2800/52

摘要： A therapeutic effect of the administration of interferon-² (IFN-²) on a relapsing-remitting multiple sclerosis (RRMS) patient can be predicted and an RRMS case, wherein the administration can be hardly continued because of the occurrence of a serious side effect or worsening of co-occurring immunological disorder, can be predicted by measuring the amount of plasma blasts (PB) in a sample from the RRMS patient. Further, the therapeutic effect of an IL-6 inhibitor in treating RRMS can be predicted by measuring the amount of PB in a sample from an RRMS patient, which enables the provision of a therapeutic method efficacious to a patient to whom IFN-² can be hardly applied in treating RRMS.

公开(公告)号：EP3144002A4

公开(公告)日：2018-02-07

申请号：EP15792520

申请日：2015-04-28

申请人： NAT CENTER OF NEUROLOGY AND PSYCHIATRY

发明人： YAMAMURA TAKASHI ,  NOTO DAISUKE ,  MIYAKE SACHIKO

IPC分类号： A61K31/715 ,  A61K31/7032 ,  A61P37/02 ,  A61P37/06 ,  A61P43/00

CPC分类号： A61K31/7032 ,  A61K31/715

摘要： The present invention provides a GM-CSF-producing T-cell control agent comprising a glycolipid compound represented by the following formula (I) or a salt thereof as an active ingredient: wherein R 1 represents an aldopyranose residue, R 2 represents a hydrogen atom or a hydroxy group, R 3 represents -CH 2 -, -CH(OH)-CH 2 -, or -CH=CH-, R 4 represents a hydrogen atom or CH 3 , x is 0 to 35, and y and z each represent an integer that satisfies y + z = 0 to 3.